Moderna, Inc. (NASDAQ:MRNA – Get Free Report) hit a new 52-week high on Monday . The company traded as high as $176.86 and last traded at $174.5570, with a volume of 16200492 shares traded. The stock had previously closed at $154.04.
Moderna News Summary
Here are the key news stories impacting Moderna this week:
- Positive Sentiment: FDA approval expands Moderna’s vaccine opportunity. Moderna’s mRNA flu vaccine has received U.S. approval and is now available to adults aged 50 and older. The product could provide a new revenue stream and demonstrate that the company’s mRNA platform can move beyond COVID-19. mRNA flu vaccine wins FDA approval, promising a faster shot
- Positive Sentiment: Melanoma vaccine data remains the primary stock catalyst. Moderna and Merck’s investigational personalized cancer vaccine, intismeran autogene, produced positive Phase 3 results in high-risk melanoma when used with Keytruda, including a reported 49% reduction in risk. Detailed results will be presented at the European Society for Medical Oncology meeting, with investors also looking ahead to a late-October data event. Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
- Positive Sentiment: Investor expectations are rising for personalized cancer treatment. Analysts and market commentators believe the upcoming presentation could validate the first personalized cancer therapy tested at scale and support future expansion into pancreatic and lung cancers. This optimism has helped drive Moderna’s substantial 2026 rally. MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going
- Neutral Sentiment: Moderna co-founder Bob Langer joined the scientific advisory board of AI-focused biotech Cellular Intelligence. The appointment links Moderna’s scientific network with AI drug discovery and Parkinson’s research, but it does not represent a new Moderna partnership or near-term financial catalyst. Moderna Tied To AI Drug Push As Bob Langer Takes New Advisory Role
- Negative Sentiment: After the extraordinary rally, MRNA’s valuation and expectations leave the stock vulnerable to profit-taking if the ESMO presentation or future cancer-vaccine data disappoints. The share price is already close to its 52-week high, making upcoming clinical results especially important.
Analyst Ratings Changes
A number of research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft started coverage on Moderna in a research note on Friday, August 28th. They issued a “hold” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a report on Wednesday, September 9th. Wolfe Research upgraded Moderna from an “underperform” rating to a “peer perform” rating in a research note on Tuesday, August 25th. Rothschild & Co Redburn cut shares of Moderna from a “neutral” rating to a “sell” rating and raised their price target for the stock from $40.00 to $81.00 in a research note on Thursday, September 3rd. Finally, Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a research report on Wednesday, August 19th. Seven investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $76.72.
Moderna Stock Performance
The company has a fifty day moving average of $104.13 and a two-hundred day moving average of $72.04. The firm has a market capitalization of $73.69 billion, a price-to-earnings ratio of -23.12 and a beta of 1.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29.
Moderna (NASDAQ:MRNA – Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.03) by $0.06. The business had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. Moderna’s revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($2.13) earnings per share. As a group, equities research analysts predict that Moderna, Inc. will post -6.09 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, President Stephen Hoge sold 40,281 shares of Moderna stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $146.07, for a total transaction of $5,883,845.67. Following the sale, the president directly owned 1,562,029 shares of the company’s stock, valued at approximately $228,165,576.03. The trade was a 2.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James M. Mock sold 34,836 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the transaction, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. The trade was a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 118,882 shares of company stock worth $16,862,280 in the last ninety days. 10.80% of the stock is owned by insiders.
Institutional Trading of Moderna
A number of hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Moderna during the 2nd quarter worth approximately $2,142,877,000. Capital World Investors acquired a new position in shares of Moderna during the 4th quarter valued at $378,299,000. Theleme Partners LLP bought a new position in Moderna during the second quarter worth $564,272,000. Norges Bank acquired a new stake in Moderna in the fourth quarter worth $79,707,000. Finally, Merck & Co. Inc. bought a new stake in Moderna in the second quarter valued at $161,642,545. 75.33% of the stock is owned by institutional investors and hedge funds.
About Moderna
Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.
The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.
Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.
Featured Articles
- Five stocks we like better than Moderna
- Lockheed’s Stock Hasn’t Priced In Its Own Backlog—Boeing’s Might Already Have
- Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?
- Old Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom
- 3 Tech Stocks Positioned for More Upside if the Sector’s Breakout Holds
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
